Education
About Us
Working with TipRanks
Follow Us
AegirBio AB (DE:52Q)
:52Q
52Q Stock Chart & Stats
Day’s Range― - ―
52-Week Range<€0.01 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€919.75K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)2.85M
Price to Earnings (P/E)―
Beta9.44
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,185,835,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
52Q FAQ
What was AegirBio AB’s price range in the past 12 months?
AegirBio AB lowest stock price was <€0.01 and its highest was €0.02 in the past 12 months.
What is AegirBio AB’s market cap?
AegirBio AB’s market cap is €919.75K.
When is AegirBio AB’s upcoming earnings report date?
AegirBio AB’s upcoming earnings report date is Aug 29, 2025 which is in 73 days.
How were AegirBio AB’s earnings last quarter?
Currently, no data Available
Is AegirBio AB overvalued?
According to Wall Street analysts AegirBio AB’s price is currently Overvalued.
Does AegirBio AB pay dividends?
AegirBio AB does not currently pay dividends.
What is AegirBio AB’s EPS estimate?
AegirBio AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AegirBio AB have?
AegirBio AB has 1,185,835,800 shares outstanding.
What happened to AegirBio AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AegirBio AB?
Currently, no hedge funds are holding shares in DE:52Q
Company Description
AegirBio AB
AegirBio AB is a Swedish diagnostic company that offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company's products include Monator - drug monitoring of tysabri in MS, Veritope, and Magniareader.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
S2Medical AB Class B
―
Qlife Holding AB
―
SpectraCure AB
―
Acarix AB
―